H.C. Wainwright raised the firm’s price target on Zymeworks (ZYME) to $13 from $12 and keeps a Neutral rating on the shares following the Q4 report. The firm believes the company’s balance sheet should be sufficient to fund operations into the second half of 2027.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ZYME:
- Zymeworks price target raised to $19 from $18 at Citi
- Zymeworks: Promising Pipeline and Financial Stability Justify Buy Rating
- Zymeworks Faces Challenges in Diagnostic Test Development Amidst Regulatory Changes
- Zymeworks’ Earnings Call: Achievements and Challenges
- Zymeworks: Hold Rating Amid Limited Near-Term Catalysts and Strategic Resource Allocation
Questions or Comments about the article? Write to editor@tipranks.com